Yake Group's Two Pharmaceutical Giants Deliver Strong Performance Gains! HK Stock Connect Innovative Drug ETF Wanjia (520700) Surges 3%, Intraday Turnover Exceeds 17%, Net Inflows Over 43 Million in a Single Day

On the market, the Hong Kong stocks’ innovative drug sector rapidly surged, with WuXi AppTec (合联) rising over 7%, WuXi Biologics (康德) up over 6%, and Ascentage Pharma (亚盛医药) increasing over 4%. As of 10:03, the Hong Kong Stock Connect Innovation Drug ETF Wanjia (520700) rose 3%, with a turnover rate exceeding 17% during the trading session and a transaction volume of 140 million yuan, indicating active market trading.

The Hong Kong Stock Connect Innovation Drug ETF Wanjia (520700) continued to attract funds, with a net inflow of 43.0612 million yuan on the previous trading day. Over the past week, the fund saw a total net inflow of 60.7244 million yuan. In the past year, the total net inflow reached 672 million yuan.

In terms of news, on March 23, WuXi AppTec released its 2025 performance report, achieving approximately 5.944 billion yuan in revenue for the year, a 46.7% increase year-over-year; gross profit was about 2.139 billion yuan, up 72.5%; net profit attributable to shareholders after adjustments was approximately 1.559 billion yuan, a 69.9% increase; net profit reached 1.48 billion yuan, up 38.4%. As of December 31, 2025, the group’s unfulfilled order total reached $1.489 billion, a 50.3% increase compared to $991 million in the same period last year.

On the same day, WuXi Biologics also disclosed its 2025 performance, with operating revenue of 45.456 billion yuan, a 15.84% increase; net profit attributable to shareholders was approximately 19.151 billion yuan, up 102.65%; net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.56%. The company plans to distribute approximately 4.712 billion yuan in cash dividends.

Guojin Securities pointed out that the turning point for loss-making innovative drug companies has arrived, with intensive clinical data catalysts throughout the year. Coupled with successful overseas clinical progress of their BD pipelines, the outlook for the innovative drug sector is optimistic. The medical device sector also shows a positive trend overall, with continuous innovation in product development, steady recovery of domestic demand, and accelerated expansion into overseas markets.

The Hong Kong Stock Connect Innovation Drug ETF Wanjia (520700) tracks the CSI Hong Kong Stock Connect Innovation Drug Index, which is constructed in a more scientific and reasonable manner. Its constituent stocks include leading companies such as BeiGene, Innovent Biologics, and WuXi Biologics. It focuses on listed companies in the Hong Kong market engaged in innovative drug research, development, manufacturing, and services. Off-market investors can explore opportunities in innovative drug development through the connect programs (Type A: 023481; Type C: 023482).

(Investments involve risks; please invest cautiously.)